Has Monteza Modaber, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,328 in general payments to Monteza Modaber, MD across 72 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Monteza Modaber, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Monteza Modaber, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Monteza Modaber, MD

Neurology · Jamaica, NYNPI 1528412368

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 28.5% of the total.

$2,328in general payments, 2019–2025

Across 72 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$663
Neurocrine Biosciences, Inc.$368
AstraZeneca$222
Medtronic$214
Ceribell, Inc.$134
Teva Pharmaceuticals USA, Inc.$122
plus $605 from 11 others

$90,564in research payments, 2019–2025

Across 23 payments — averaging $3937.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$91K

What the payments were for

Food & beverage$2,328100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	33	$663
Neurocrine Biosciences, Inc.	11	$368
AstraZeneca(2 entities)	3	$222
Medtronic	2	$214
Ceribell, Inc.	1	$134
Teva Pharmaceuticals USA, Inc.	4	$122
Boehringer Ingelheim	1	$117
Neurasignal Inc.	1	$95
Medical Device Business Services, Inc.	1	$78
Biogen	4	$67
Acadia Pharmaceuticals Inc	3	$62
Amgen	2	$54
EMD Serono, Inc.	2	$45
UCB, Inc.	1	$26
Lundbeck LLC	1	$24
Lilly USA, LLC	1	$20
Impel Pharmaceuticals Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,328 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024

$42,182

Medicare patients

229

Services billed

358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Donepezil Hcl	67	$429
Duloxetine Hcl	22	$368
Cilostazol	17	$359
Gabapentin	46	$288
Celecoxib	12	$277
Carbidopa-LevodopaCarbidopa/Levodopa	18	$248
Memantine Hcl	24	$196
Lamotrigine	13	$194
Atorvastatin Calcium	11	$167
Tizanidine Hcl	18	$156
Topiramate	27	$156
Quetiapine Fumarate	21	$134
Pregabalin	12	$98

Paid to pharmacies, not to this prescriber.

Other neurology in Jamaica

Idan SharonBrooklyn$2.1M
Allan PerelStaten Island$1.7M
Nicolas SaikaliAmherst$1.5M
David KreitzmanCommack$1.5M
Charles ArgoffAlbany$1.2M
Stephen KriegerNew York$1.1M
Robert FeketeHawthorne$1M
Jennifer McVigeAmherst$982K
Warren SpinnerPort Jefferson Station$791K
Richard LiptonBronx$753K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →